BiotechTube

Infliximab + Prednisolone + Azathioprine

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Crohn's Disease

Conditions

Crohn's Disease

Trial Timeline

Apr 1, 2015 → Jan 1, 2024

NCT ID
NCT02517684

About Infliximab + Prednisolone + Azathioprine

Infliximab + Prednisolone + Azathioprine is a approved stage product being developed by Pfizer for Crohn's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02517684. Target conditions include Crohn's Disease.

What happened to similar drugs?

8 of 20 similar drugs in Crohn's Disease were approved

Approved (8) Terminated (4) Active (12)
✅adalimumabAbbVieApproved
✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved
✅Celebrex + placeboPfizerApproved
✅Cimzia + MesalamineUCBApproved
✅Certolizumab PegolUCBApproved
✅certolizumab pegol + certolizumab pegol + certolizumab pegol + certolizumab pegolUCBApproved
✅natalizumabBiogenApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02517684ApprovedCompleted

Competing Products

20 competing products in Crohn's Disease

See all competitors
ProductCompanyStageHype Score
CT-P13 + RemicadeCelltrionPhase 3
40
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
29
CT-P13 SC (Infliximab)CelltrionPhase 3
40
CP-461Astellas PharmaPhase 2
35
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
32
E6011 + PlaceboEisaiPhase 2
35
E6011 + PlaceboEisaiPhase 1
21
adalimumab + adalimumab + placeboEisaiPhase 2/3
38
adalimumabEisaiPhase 2/3
38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
40
MirikizumabEli LillyPhase 3
47
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
47
Mirikizumab + PlaceboEli LillyPhase 2
35
MirikizumabEli LillyPhase 3
44
Matching Placebo for Upadacitinib + UpadacitinibAbbViePhase 3
40
Adalimumab + PlaceboAbbViePhase 3
40
Upadacitinib + Placebo for UpadacitinibAbbViePhase 3
40
Placebo + ABT-494AbbViePhase 2
35
ABT-494AbbViePhase 2
35
Risankizumab + ComparatorAbbViePre-clinical
33